Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BT-001 |
Synonyms | |
Therapy Description |
BT-001 is an engineered oncolytic vaccinia virus expressing GM-CSF and anti-CTLA4 antibody, which may trigger enhanced anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 5602). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BT-001 | BT 001|BT001 | BT-001 is an engineered oncolytic vaccinia virus expressing GM-CSF and anti-CTLA4 antibody, which may trigger enhanced anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 5602). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |